In Review: PCMA submitted a comment letter on the New Hampshire Prescription Drug Affordability Board’s (PDAB) 2024 Annual Report. PCMA believes several statements, citations, and studies that board members never discussed or agreed upon included in the report. The PDAB will review PCMA’s comments and will respond by the next PDAB meeting at the end of February.
If you have any questions, please contact Sam Hallemeier at shallemeier@pcmanet.org.
